Clinical Trials Logo

Filter by:
NCT ID: NCT04049448 Completed - Clinical trials for Rheumatoid Arthritis

Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

Start date: October 24, 2019
Phase: Phase 2
Study type: Interventional

A phase 2a open-label study to evaluate the long-term safety and efficacy of ABX464 50mg as maintenance therapy in patients with moderate to severe rheumatoid arthritis.

NCT ID: NCT04047511 Completed - Depression Clinical Trials

Virtual Therapy as a Method Supporting Treatment of Late-Life Depression

Start date: June 1, 2019
Phase: N/A
Study type: Interventional

This study evaluates the addition of virtual therapy intervention in the treatment of depression in the elderly. Half of the participants will receive virtual reality treatment as an addition to physical exercises and psychoeducation, while the other half will receive physical exercises and psychoeducation alone.

NCT ID: NCT04045977 Completed - Clinical trials for Coronary Artery Disease

Virtual Therapy as a Method Supporting the Cardiac Rehabilitation

Start date: June 6, 2019
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of virtual reality (VR) therapy in the treatment of depression and anxiety symptoms in patients undergoing second stage of cardiac rehabilitation. Half of the study group will receive VR therapy (VR group) as an addition to cardiologically monitored physical training. The other half of the group (control group) will receive Schultz Autogenic Training as a standard supplement to cardiological training.

NCT ID: NCT04045613 Completed - Clinical trials for Urothelial Carcinoma

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

FIDES-02
Start date: August 2, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.

NCT ID: NCT04043806 Completed - Cystic Fibrosis Clinical Trials

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Start date: August 9, 2019
Phase: Phase 3
Study type: Interventional

This study evaluated the long-term safety and tolerability of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) triple combination (TC) treatment in participants with cystic fibrosis (CF).

NCT ID: NCT04042454 Completed - Diarrhea Clinical Trials

To Assess the Safety and Tolerance of Infant Formula With Locust Bean Gum in Infants With Regurgitation

Solar
Start date: December 10, 2019
Phase: N/A
Study type: Interventional

A randomized, controlled study to evaluate the safety and tolerance of an infant formula with locust bean gum in infants with regurgitation. (Solar)

NCT ID: NCT04041609 Completed - Chronic Sinusitis Clinical Trials

LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase II, Randomized, Blinded, Sham Procedure-Controlled, Parallel-Group Trial to Evaluate the Efficacy, Safety and Tolerability of LYR-210 in Adult Subjects with Chronic Sinusitis.

NCT ID: NCT04041284 Completed - Clinical trials for Major Depressive Disorder

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Start date: September 13, 2019
Phase: Phase 4
Study type: Interventional

The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg sc of fremanezumab in adult participants with migraine and MDD on the reduction of MDD symptoms, responder rates in monthly migraine days, improving quality of life, improving disability, and the safety and tolerability of monthly 225 mg sc and quarterly 675 mg sc fremanezumab in adult participants with migraine and MDD. The total duration of participant participation in the study is planned to be approximately 28 weeks.

NCT ID: NCT04039997 Completed - Resuscitation Clinical Trials

How to Learn Cardiopulmonary Resuscitation

Start date: July 20, 2019
Phase: N/A
Study type: Interventional

the aim of the study is to evaluate two methods of teaching cardiopulmonary resuscitation in the context of chest compression quality. We will evaluate the usefulness of the application cpr feedback device (CPRMeter) for quality of chest compression.

NCT ID: NCT04039503 Completed - Type 2 Diabetes Clinical Trials

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

SURPASS-5
Start date: August 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.